This is a preview of subscription content, log in via an institution to check access.
References
Kauffman R.F., Bryant H.U. Selective estrogen receptor modulators. Drug News and Perspectives 1995, 8: 531–539.
Black L.J., Sato M., Rowley E.R., Magee D.E., Bekele A., Williams D.C., Cullinan G.J., Bendele R., Kaufman R.F., Bensch W.R., Frolik C.A., Termine J.D., Bryant H.U. Raloxifene (LY138481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Clin. Invest. 1994, 93: 63–69.
Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D., Arnaud C.D. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. Bone Miner. Res. 1996, 11: 835–842.
Bryant H.U., Dere W.H. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc. Soc. Exp. Biol. Med. 1998, 217: 45–52.
Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. Natl. Cancer Inst. 1998, 90: 1371–1388.
Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy A., Viggers J., Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352: 98–101.
Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the italian randomised trial among hysterectomised women. Lancet 1998, 352: 93–97.
Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Natl. Cancer Inst. 1994, 86: 527–537.
Delmas P.D., Bjarnason N.H., Mitlak B., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. Engl. J. Med. 1997, 337: 1641–1647.
Hol T., Cox M.B., Bryant H.U., Draper M.W. Selective estrogen receptor modulators and postmenopausal women’s health. Women’s Health 1997, 6: 523–531.
Davies G.C., Huster W.J.L.Y., Plouffe L.J., Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet. Gynecol. 1999, 93: 558–565.
Lu Y., Cohen F.J., Lakshmanan M. Characterization of hot flashes during raloxifene therapy: analyses of adverse event reports from an integrated placebo-controlled clinical trial database. Menopause 1998, 95: 98 (Abstract).
Kniffin W.D.J., Baron J.A., Barrett J., Birkmeyer J.D., Anderson F.A. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch. Intern. Med. 1994, 154: 861–866.
Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1996, 344: 1453–1457.
Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348: 977–980.
Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., Willet W.C., Hennekens C.H. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996, 348: 983–987.
Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348: 981–983.
Gutthann S.P., Rodriguez L.A.G., Castellsague J., Oliart A.D. Hormone replacement therapy and risk of venous thromboembolism: population based case control study. BMJ 1997, 314: 796–800.
Hulley S.B., Grady D., Bush T.L., Furberg C., Herrington D., Riggs B.L., et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280: 605–613.
Schneider L.S., Finch C.E. Can estrogens prevent neurodegeneration? Drugs Aging 1997, 11: 87–95.
Paganini-Hill A., Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch. Intern. Med. 1996, 156: 2213–2217.
Yaffe C., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 1998, 279: 688–695.
Nickelsen T., Lufkin E.G., Riggs B.L., Cox D.A., Crook T.H. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999, 24: 115–128.
Lorenzo A., Diaz H., Carrer H.F., Cacaeres A. Amygdala neurons in vitro: neurite growth and effects of estradiol. Neurosci. Res. 1992, 33: 418–435.
Nilsen J., Mor G., Naftolin F. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 1998, 5: 211–216.
Nevitt M.C., Ettinger B., Black D.M., Stone K., Jamal S.A., Ensrud K., Segal M., Genant H.K., Cummings S.R. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 1998, 128: 793–800.
Lips P., Cooper C., Agnusdei D., Caulin F., Egger P., Johnell O., Kanis J.A., Liberman U., Minne H.W., Reeve J., Reginster J.Y., De Vernejoul M.C., Wiklund I. Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporosis Int. 1997, 7: 36–38.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Agnusdei, D., Iori, N. Tolerability profile of SERMs. J Endocrinol Invest 22, 641–645 (1999). https://doi.org/10.1007/BF03343622
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343622